

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Berka et al.

SERIAL NUMBER: 10/767,899

EXAMINER: Not Yet Assigned

FILING DATE: January 28, 2004

ART UNIT: Not Yet Assigned

FOR: BEAD EMULSION NUCLEIC ACID AMPLIFICATION

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Cited References A1-A5, B1-B7 and C1-C7; and
4. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21465-508 UTIL. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


Ivor Elrifi, Reg. No. 39,529
Caryn DeHoratius, Reg. No. 45,881
Attorney/Agent for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue
New York, New York 10017
Phone: (212) 935-3000
Fax: (212) 983-3115

Dated: June 18, 2004



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Berka et al.

SERIAL NUMBER: 10/767,899

EXAMINER: Not Yet Assigned

FILING DATE: January 28, 2004

ART UNIT: Not Yet Assigned

FOR: BEAD EMULSION NUCLEIC ACID AMPLIFICATION

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants: Berka et al.
U.S.S.N.: 10/767,899

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21465-508 UTIL.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Caryn DeHoratius, Reg. No. 45,881
Attorney/Agent for Applicant
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY & POPEO P.C.
Chrysler Center
666 Third Avenue
New York, New York 10017
Tel: (212) 935-3000
Fax: (212) 983-3115

Dated: June 18, 2004

NYC 291556v1

Express Mail Label No.: EV399525384US
Date of Deposit: June 18, 2004

1 of 1

Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number 10/767,899
		Filing Date January 28, 2004
		First Named Inventor Berka
		Group Art Unit Not Yet Assigned
		Examiner Name Not Yet Assigned
		Attorney Docket Number 21465-508 UTIL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
	A1	5,989,892	11/23/99	Nishimaki et al.	435	252.1	06/13/96
	A2	6,023,540	02/08/00	Walt et al.	385	12	03/14/97
	A3	6,184,012	02/06/01	Neri et al.	435	188	04/25/97
	A4	6,266,459	07/24/01	Walt et al.	385	12	11/29/99
	A5	6,489,103	12/03/02	Griffiths et al.	435	6	12/16/99

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
B1	WO	97/40141	Medical Research Council	October 30, 1997	X
B2	WO	99/02671	Medical Research Council	January 21, 1999	X
B3	WO	00/40712	Medical Research Council	July 13, 2000	X
B4	WO	01/18244	Medical Research Council	March 15, 2001	X
B5	WO	02/22869	Medical Research Council	March 21, 2002	X
B6	WO	02/103363	Medical Research Council	December 27, 2002	X
B7	WO	03/044187	Medical Research Council	May 30, 2003	X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C1		Bauer, Johann (1999). <i>J. Chromatography</i> <u>722</u> : 55-69.
C2		Brody & Quake (1999). <i>Applied Physics Letters</i> <u>74</u> : 144-146.
C3		Dressman et al. (2003). <i>PNAS</i> <u>100</u> : 8817-8822.
C4		Ghadessy et al. (2001). <i>PNAS</i> <u>99</u> : 4552-4557.
C5		Griffiths & Tawfik (2003). <i>EMBO J.</i> <u>22</u> : 24-35.
C6		Sepp et al. (2002). <i>FEBS Letters</i> <u>532</u> : 455-458.
C7		Tawfik & Griffiths (1998). <i>Nat Biotechnol</i> <u>16</u> : 652-656.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.